By Bernadette Toner

NEW YORK (GenomeWeb) – NanoString Technologies' newly appointed executive chairman is looking to drive the company's digital barcoding technology into the clinical diagnostics market by positioning the nCounter platform as an "elegantly simple" alternative to qPCR and other diagnostic methods.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.